血小板中单胺氧化酶活性降低:可能是易患精神分裂症的遗传标志物
Science (New York, N.Y.)
|March 2, 1973
概括
血小板中单胺氧化酶 (MAO) 活性降低可能表明对精神分裂症的遗传脆弱性. 这一发现在受影响的个体和他们的健康双胞胎中都被观察到,这表明该疾病的潜在生物标志物.
科学领域:
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
- 遗传学 是一个遗传学.
背景情况:
- 精神分裂症是一种复杂的精神疾病,具有重要的遗传成分.
- 单胺氧化酶 (MAO) 是一种参与神经递质代谢的酶,其活性与各种精神疾病有关.
- 血小板为研究体内MAO活性提供了一个易于访问的来源.
研究的目的:
- 研究精神分裂症患者及其未受影响的双胞胎中的血小板单胺氧化酶 (MAO) 活性.
- 探索MAO活性与精神分裂症症状的严重程度之间的关系.
- 为了确定减少MAO活性是否可以作为精神分裂症脆弱性的遗传标记.
主要方法:
- 在血小板中测量了单胺氧化酶 (MAO) 活性,使用[(14) C]三胺作为基质.
- 这项研究包括13对对单胞胎双胞胎,这些双胞胎对精神分裂症不一致,以及23名健康的志愿者.
- 精神分裂症程度的测量与MAO活性相关.
主要成果:
- 与正常志愿者相比,精神分裂症患者及其非精神分裂症双胞胎的血小板单胺氧化酶 (MAO) 活性显著降低.
- MAO活性显示出单胞胎双胞胎之间的高相关性.
- 在精神分裂症的严重程度和血小板MAO活性之间发现了显著的反相关性.
结论:
- 降低血小板单胺氧化酶 (MAO) 活性可能是与精神分裂症相关的遗传性特征.
- 这些发现表明,血小板MAO活性可能成为易患精神分裂症的遗传标记.
- 需要进一步的研究来证实这些结果并阐明潜在的机制.
相关概念视频
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Biological Causes of Schizophrenia
Schizophrenia, a severe psychiatric disorder, arises from a complex interplay of biological factors, including genetic predisposition, structural brain abnormalities, neurotransmitter dysregulation, and developmental irregularities. These factors collectively contribute to the onset and progression of the disorder, which typically manifests in late adolescence or early adulthood.
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin studies.
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin studies.